CrushSCI.com
提供学术论文选刊润色服务
BMC CANCER 期刊封面 医学
返回期刊列表

Review Cycle Records

BMC CANCER

Springer SCIE OA
2026新锐 2区2025中科院 3区2025 JCR Q2
154.9平均天数
100中位天数
35最短天数
390最长天数
2,1032025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

117 天

The impact of chemotherapy on frontal lobe executive functioning in adolescents and young adults diagnosed and treated for blood cancers: a systematic review

作者Raina Patwardhan; Clare Jacobson; Jaishibani Mande Nagarajan; Lee D Hudson

作者单位1. Great Ormond Street UCL Institute of Child Health, London, UK; 2. Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 3. Peninsula Medical School, University of Plymouth, Plymouth, UK

PDF源文件 DOI 网页
178 天

Role of CDC25B in human cancers: a meta-analysis and bioinformatics analysis

作者Shuguang Li; Ying Li; Ting Liu

作者单位1. Department of Orthopedic, Beijing Ditan Hospital, Capital Medical University, Beijing, China; 2. Department of Pathology, The Fourth Medical Center of the PLA General Hospital, Beijing, China; 3. Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China

PDF源文件 DOI 网页
285 天

From overweight/obesity to metabolic syndrome: increased postoperative survival risk in gastric cancer

作者Yan-Ting Li; Juan-Li Zhang; Min Lai; Min Chen; Zhuan-mei Jin; Xiao-li Wu; Wen-Zhen Yuan

作者单位1. The First Clinical Medical College of Lanzhou University, Lanzhou, P.R. China; 2. Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, P. R. China; 3. Department of Surgical Oncology, The First Hospital of Lanzhou University, Lanzhou, P. R. China

PDF源文件 DOI 网页
373 天

Trials in progress: CARMAN – study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance

作者Marie-Kristin Tilch; Christian Schmidt; Marek Trneny; Eva Giné; Olivier Hermine; Anke Ohler; Stephanie Herold; Eva Hoster; Linmiao Jiang; Christiane Pott; Martin Dreyling; Georg Hess

作者单位1. Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 2. Department of Internal Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, LMU Medizin, Munich, Germany; 3. First Department of Internal Medicine -Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic; 4. Department of Hematology, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain; 5. CEREMAST Necker Hospital, Paris, France; 6. Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, LMU Munich, Munich, Germany; 7. Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany

PDF源文件 DOI 网页
35 天

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all- trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

作者Olga Grishina; Claudia Schmoor; Caroline Sellner; Björn Hackanson; Jan-Henrik Mikesch; Iordanis Deligiannis; Felicitas Thol; Martina Crysandt; Christian Junghanss; Volker Runde; Paul La Rosée; Lino Lars Teichmann; Haifa Kathrin Al-Ali; Tim Sauer; Ulrich Germing; Frank Griesinger; Stefan Lukic; Jürgen Krauter; Snjezana Janjetovic; Jan Koch; Peter Staib; Julian Topaly; Maike de Wit; Doris Maria Kraemer; Lorenz Oelschläger; Ulf Schnetzke; Oliver Schmah; Swen Wessendorf; Cyrus Khandanpour; Lukas Kündgen; Monika Schwalenberg; Michael Heuser; Arnold Ganser; Hartmut Döhner; Ralph Wäsch; Michael Lübbert

作者单位1. Clinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany; 2. Department of Hematology/Oncology, Comprehensive Cancer Center Augsburg as Part of the CCC-WERA Consortium, University Medical Center Augsburg, Augsburg, Germany; 3. Department of Medicine A, University Hospital Münster, Münster, Germany; 4. Internal Medicine I, Brothers Hospital Trier, Trier, Germany; 5. Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany; 6. Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachen, Germany; 7. Department of Internal Medicine, Clinic for Hematology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Hemostasis, Rostock, Germany; 8. Department of Hematology, Oncology and Palliative Care, Wilhelm-Anton- Hospital, Goch, Germany; 9. Department for Internal Medicine II, Schwarzwald‐Baar Klinikum, Villingen-Schwenningen, Germany; 10. Department of Medicine III, University Hospital Bonn, Bonn, Germany; 11. Krukenberg Cancer Center Halle, Medical Faculty, Martin-Luther- University Halle-Wittenberg, Halle (Saale), Germany; 12. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; 13. Department of Hematology, Oncology, and Clinical Immunology, Heinrich- Heine University Düsseldorf, Düsseldorf, Germany; 14. Clinic for Hematology and Oncology, Pius-Hospital Oldenburg, University Medicine Oldenburg, Oldenburg, Germany; 15. Department of Hematology and Oncology, Augusta-Kranken-Anstalt, Academic Teaching Hospital of the Ruhr-University Bochum, Bochum, Germany; 16. Department of Hematology and Oncology, Municipal Hospital Braunschweig, Braunschweig, Germany; 17. Department of Hematology and Cell Therapy, Helios Klinikum Berlin- Buch, Berlin, Germany; 18. University Medical Center Mannheim (UMM), Mannheim, Germany; 19. Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany; 20. Department of Hematology and Oncology, CaritasKlinikum Saarbrücken, Saarbrücken, Germany; 21. Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany; 22. St. Josefs-Hospital Hagen, Hagen, Germany; 23. Department of Hematology and Oncology, Schleswig-Holstein, University Medical Center, University Cancer Center Schleswig-Holstein, Lübeck, Germany; 24. Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University Hospital Jena, Jena, Germany; 25. Section of Hematology and Oncology, Ortenau Medical Care Center, Ortenau Klinikum Lahr, Lahr, Germany; 26. Department of Hematology and Oncology, Klinikum Esslingen, Esslingen, Germany; 27. University Clinic for Internal Medicine – Oncology and Hematology, Oldenburg Medical Center, University of Oldenburg, Oldenburg, Germany; 28. Department of Hematology, Oncology, Infectious Diseases and Palliative Care, Municipal Hospital Karlsruhe, Karlsruhe, Germany; 29. Department of Hematology, Oncology and Palliative Care, Hospital Lüdenscheid, Lüdenscheid, Germany; 30. Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany; 31. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; 32. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。